Impact of Steatotic Liver Disease Associated With Metabolic Dysfunction (MASLD) on Frailty, Cognition, and Quality of Life. A Gender-sensitive Approach Towards a Comprehensive and Equitable Perspective.

Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau140 enrolled

Overview

The goal of this observational study is to determine the differences in the prevalence, characteristics and evolution of frailty between men and women diagnosed with MASLD, and to establish its relationship with clinical, functional, hormonal and social parameters.

Study Type

OBSERVATIONAL

Enrollment

140

Conditions

Steatosis of Liver

Eligibility

Sex: ALLMin age: 20 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients will be included who are able to provide informed consent and actively participate in periodic assessments. Exclusion Criteria: * Risky alcohol consumption: \> 30 g/day in men and \> 20 g/day in women. AUDIT score: \> 7 points in men, \> 5 in women. * Other liver diseases (viral hepatitis, autoimmune hepatitis, etc.). * Advanced neurodegenerative diseases or severe psychiatric disorders. * Severe comorbidities or treatments that, in the researchers' judgment, may affect frailty and quality of life more than metabolic syndrome and liver disease.

Locations (2)

Hospital de la Santa Creu i Sant Pau

Barcelona, Barcelona, Spain

Outcomes

Primary Outcomes

Change in Liver Frailty Index (LFI) score

Change in Liver Frailty Index (LFI) score from baseline to follow-up. Higher values indicate worsening frailty, whereas lower values indicate improvement in frailty.